Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
- Address
- Ul. Woloska 137, 02-507 Warsaw, Poland
Skin and Connective Tissue Diseases
The department is conducting studies that aim to evaluate new therapeutic options for a range of skin conditions, from inflammatory disorders to rare ulcerative diseases.
- alopecia areata
- atopic dermatitis
- chronic spontaneous urticaria
- hidradenitis suppurativa
- moderate-to-severe plaque psoriasis
- prurigo nodularis
- ulcerative pyoderma gangrenosum
- systemic sclerosis
Researchers at the Panstwowy Instytut Medyczny are testing novel topical and systemic agents to improve symptom control and quality of life for patients with these dermatologic and connective‑tissue disorders.
Immune System Diseases
Trials focus on modulating immune pathways to reduce disease activity in conditions driven by dysregulated immunity.
- chronic spontaneous urticaria
- atopic dermatitis
- moderate-to-severe plaque psoriasis
- hidradenitis suppurativa
The site evaluates innovative biologics and small‑molecule inhibitors to determine whether they can safely suppress the underlying immune activation associated with these diseases.
Respiratory Tract Diseases
Research aims to identify treatments that improve lung function and reduce exacerbations in patients with severe airway inflammation.
- inadequately controlled moderate to severe asthma
At the Warsaw clinic, investigators are assessing novel inhaled and systemic agents to see if they can provide better symptom relief and prevent disease progression.
Nutritional and Metabolic Diseases
Studies are designed to test interventions that target weight management and glycaemic control, addressing the growing burden of metabolic disorders.
- obesity
- overweight
- type 1 diabetes mellitus
- type 2 diabetes mellitus
The clinical program includes both lifestyle‑based approaches and pharmacologic therapies to determine their effectiveness in reducing disease complications.
Female Urogenital Diseases and Pregnancy Complications
The focus is on alleviating painful menstrual symptoms through novel therapeutic agents.
- primary dysmenorrhea
Researchers at the institute are conducting randomized studies to see whether botanical extracts can safely reduce cramping and improve daily functioning for women.
Digestive System Diseases
Clinical investigations target inflammatory bowel conditions, seeking therapies that induce remission and sustain mucosal healing.
- ulcerative colitis
- colitis ulcerative
- ulcerative pyoderma gangrenosum
The Warsaw site compares investigational agents with established biologics to evaluate whether patients achieve faster symptom relief and longer periods of disease control.
Bacterial Infections and Mycoses
Although not the primary focus, the department monitors skin‑related infectious conditions to ensure comprehensive patient care.
- assessment of adjunctive therapies for bacterial skin infections
- evaluation of antifungal treatments for chronic dermatomycoses
Ongoing observational studies at the institute help define optimal management strategies for these infections alongside dermatologic research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 17 therapeutic areas and 15 of 171 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 164 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 41 by active trials.
- 1AstraZeneca AB6active
lock +40 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S14trials
lock +29 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
lock Showing 1 of 164 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 171 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 9 | Unknown | 2023-11-07 | 2026-04-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.